Proprietary AI analyst is now available

HeartSciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for HeartSciences and similar public comparables like Genomed, CurveBeam AI, Ayfie International, Biomaxima and more.

HeartSciences Overview

About HeartSciences

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.


Founded

2007

HQ

United States

Employees

24

Financials (LTM)

Revenue: $111K
EBITDA: ($8M)

EV

$10M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

HeartSciences Financials

HeartSciences reported last 12-month revenue of $111K and negative EBITDA of ($8M).

In the same LTM period, HeartSciences generated $64K in gross profit, ($8M) in EBITDA losses, and had net loss of ($9M).


HeartSciences P&L

In the most recent fiscal year, HeartSciences reported revenue of $4K and EBITDA of ($8M).

HeartSciences is unprofitable as of last fiscal year, with gross margin of 57%, EBITDA margin of (182759%), and net margin of (201500%).

See analyst estimates for HeartSciences
LTMLast FY202320242025202620272028
Revenue$111K$4K$14K$9K$1K
Gross Profit$64K$2K$9K$6K$1K
Gross Margin57%57%65%64%57%
EBITDA($8M)($8M)($6M)($7M)($8M)
EBITDA Margin(7345%)(182759%)(43438%)(82160%)(550272%)
EBIT Margin(7421%)(192013%)(44214%)(84289%)(559829%)
Net Profit($9M)($9M)($7M)($8M)($9M)
Net Margin(7842%)(201500%)(46198%)(88409%)(592304%)
Net Debt-$1M---

Financial data powered by Morningstar, Inc.

HeartSciences Stock Performance

HeartSciences has current market cap of $10M, and enterprise value of $10M.


HeartSciences' stock price is $2.90.

HeartSciences has an EPS (earnings per share) of $-2.66.

See more trading valuation data for HeartSciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$10M$10M-2.5%---$-2.66

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

HeartSciences Valuation Multiples

HeartSciences trades at 90.0x EV/Revenue multiple, and (1.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for HeartSciences

HeartSciences Financial Valuation Multiples

As of June 27, 2026, HeartSciences has market cap of $10M and EV of $10M.

HeartSciences has a P/E ratio of (1.1x).

LTMLast FY202320242025202620272028
EV/Revenue90.0xn/mn/mn/mn/m
EV/EBITDA(1.2x)(1.3x)(1.6x)(1.3x)(1.3x)
EV/EBIT(1.2x)(1.2x)(1.6x)(1.3x)(1.2x)
EV/Gross Profit157.5xn/mn/mn/mn/m
P/E(1.1x)(1.1x)(1.5x)(1.2x)(1.1x)
EV/FCF-(1.3x)(1.7x)(1.4x)(1.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified HeartSciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

HeartSciences Margins & Growth Rates

HeartSciences decreased revenue by 100% and EBITDA by 1% in the last fiscal year.

In the most recent fiscal year, HeartSciences reported gross margin of 57%, EBITDA margin of (182759%), and net margin of (201500%).

See estimated margins and future growth rates for HeartSciences

HeartSciences Margins

Last FY202420252026202720282029
Gross Margin57%64%57%57%
EBITDA Margin(182759%)(82160%)(550272%)(1936%)
EBIT Margin(192013%)(84289%)(559829%)(1943%)
Net Margin(201500%)(88409%)(592304%)(2021%)
FCF Margin(171108%)(77223%)(513323%)-

HeartSciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(100%)(36%)(84%)32084%
Gross Profit Growth(100%)(36%)(86%)32289%
EBITDA Growth(1%)22%7%13%
EBIT Growth(4%)23%6%12%
Net Profit Growth(3%)23%7%10%
FCF Growth-16%6%-

Data powered by FactSet, Inc. and Morningstar, Inc.

HeartSciences Operational KPIs

HeartSciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.

HeartSciences' Rule of 40 is 30148% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

HeartSciences' Rule of X is 78274% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for HeartSciences
LTMLast FY202320242025202620272028
Rule of 40(6816%)30148%---
Bessemer Rule of X(6022%)78274%---
Revenue per Employee-$0.0M---
Opex per Employee-$0.3M---
R&D Expenses to Revenue3020%100990%19405%42677%247956%
Opex to Revenue-192070%44278%84353%576210%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

HeartSciences Competitors

HeartSciences competitors include Genomed, CurveBeam AI, Ayfie International, Biomaxima, Predilife, Synthetic MR, Immunovia, Baseig, OODA AI and Genetic Analysis.

Most HeartSciences public comparables operate across Medical Imaging & Diagnostics, Pure-Play AI Software, HealthTech, Generative AI and Longevity.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Genomed1.0x-5.8x-
CurveBeam AI2.2x2.3x(2.5x)(2.5x)
Ayfie International5.0x-(2.6x)-
Biomaxima1.1x0.8x12.0x7.5x
Predilife22.6x-(3.5x)-
Synthetic MR0.4x0.4x(1.0x)(1.7x)
Immunovia66.5x35.5x(0.9x)(0.8x)
Baseig11.4x-19.3x-

This data is available for Pro users. Sign up to see all HeartSciences competitors and their valuation data.

Start Free Trial

HeartSciences VC Funding History

Before going public, HeartSciences raised $23M in total equity funding, across 3 rounds.


HeartSciences Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Dec-19Series A-$7M-HeartSciences is a medical technology company. It reported minimal revenue of $0.004 million over a nine-month period covered in its 10-Q filing, with $0.00 million for the three-month period. No details on funding rounds, valuations, or EBITDA were identified for the approximate date of November 12, 2019.
Jan-17Series A-$12M--
Jul-15Seed-$4M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About HeartSciences

When was HeartSciences founded?HeartSciences was founded in 2007.
Where is HeartSciences headquartered?HeartSciences is headquartered in United States.
How many employees does HeartSciences have?As of today, HeartSciences has over 24 employees.
Is HeartSciences publicly listed?Yes, HeartSciences is a public company listed on Nasdaq.
What is the stock symbol of HeartSciences?HeartSciences trades under HSCS ticker.
When did HeartSciences go public?HeartSciences went public in 2022.
Who are competitors of HeartSciences?HeartSciences main competitors include Genomed, CurveBeam AI, Ayfie International, Biomaxima, Predilife, Synthetic MR, Immunovia, Baseig, OODA AI, Genetic Analysis.
What is the current market cap of HeartSciences?HeartSciences' current market cap is $10M.
What is the current revenue of HeartSciences?HeartSciences' last 12 months revenue is $111K.
What is the current revenue growth of HeartSciences?HeartSciences revenue growth (NTM/LTM) is 529%.
What is the current EV/Revenue multiple of HeartSciences?Current revenue multiple of HeartSciences is 90.0x.
Is HeartSciences profitable?No, HeartSciences is not profitable.
What is the current EBITDA of HeartSciences?HeartSciences has negative EBITDA and is not profitable.
What is HeartSciences' EBITDA margin?HeartSciences' last 12 months EBITDA margin is (7345%).
What is the current EV/EBITDA multiple of HeartSciences?Current EBITDA multiple of HeartSciences is (1.2x).
How many companies HeartSciences has acquired to date?HeartSciences hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies HeartSciences has invested to date?HeartSciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to HeartSciences

Lists including HeartSciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial